医学
淋巴瘤
内科学
肿瘤科
血液学
滤泡性淋巴瘤
免疫学
疾病
作者
Na Li,Ming Jiang,Wanchun Wu,Liqun Zou
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-10-01
卷期号:18 (32): 3573-3583
标识
DOI:10.2217/fon-2022-0307
摘要
Aims: Progression of disease within 24 months (POD24) is associated with poor survival in some subtypes of lymphoma.The aim is to identify high-risk patients with localized extranodal natural killer/T-cell lymphoma (ENKTL) and to define clinical factors associated with the risk of early recurrence after antitumor treatment. Methods: The authors retrospectively analyzed 330 cases with localized ENKTL, of which 89 experienced POD24. Results: The 5-year overall survival of the POD24 group was extremely inferior to that of the non-POD24 group. Risk factors for POD24 were Eastern Cooperative Oncology Group performance status ≥2, response evaluation (non-complete remission) after first-line treatment and elevated lactate dehydrogenase concentrations. Also, higher Epstein-Barr virus DNA titer was related to POD24. Based on these data with or without the availability of Epstein-Barr virus DNA, the authors conducted two nomograms to predict POD24, which showed good accuracy with high C statistics. Conclusion: The results showed that POD24 could serve as a marker to identify patients whose medical needs were unmet in ENKTL.
科研通智能强力驱动
Strongly Powered by AbleSci AI